Pfizer Corporation

Wyeth

Abbvie Stemcentrx LLC

Stemcentrx, Inc.

Puja Sapra

Lioudmila Tchistiakova

Kiran Khandke

Scott J Dylla

Kimberly Ann Marquette

Marc Isaac Damelin

Alexander John Bankovich

Dangshe Ma

John Francis DiJoseph

Hans-Peter Gerber

Kiran Manohar Khandke

Pavel Strop

Edmund Graziani

Lawrence Nathan Tumey

Eric M Bennett

Yijie Gao

Bin-Bing Stephen Zhou

Kenneth G Geles

Fang Jin

Boris Shor

Frank Loganzo, Jr

Lioudmila Gennadievna Tchistiakova

Edmund Idris Graziani

Kimberley Ann Marquette

Nadira Anarkali Prashad

John Francis Dijoseph

The present invention provides site specific HER2 antibody drug conjugates and methods for preparing and using the same.

Site specific HER2 antibody drug conjugates

This invention relates to combinations of an auristatin or an auristatin-based antibody-drug-conjugate (ADC) with second active agents including PI3K/mTOR inhibitors, MEK inhibitors, taxanes, or other anti-cancer agents, and methods of treating abnormal cell growth by administering these combinations to patients.

Synergistic auristatin combinations

The present invention provides for anti-EFNA4 antibody-drug conjugates and methods for preparing and using the same.

Anti-EFNA4 antibody-drug conjugates

Disclosed herein are anti-IL-13-R&#x3b1;2 antibodies and antibody drug conjugates and methods for preparing and using the same.

Anti-IL-13 receptor alpha 2 antibodies and antibody-drug conjugates

The present invention provides anti-PTK7 antibody-drug conjugates and methods for preparing and using the same.

Anti-PTK7 antibody-drug conjugates

The present invention provides for anti-Notch3 antibodies, anti-Notch3 antibody-drug conjugates and methods for preparing and using the same.

Anti-Notch3 antibodies and antibody-drug conjugates

Disclosed are anti-5T4 antibody drug conjugates and methods for preparing and using the same.

Antibody-drug conjugates

Growing community of inventors

River Edge, NJ, United States of America

Puja Sapra